Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-201 Expanded Access Program for RET-Activated Solid Tumors
2023-507678-42-00Phase 4Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of selpercatinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), colon cancer and 4 more, sponsored by Eli Lilly and Company. Planned start Jul 2024; status: authorised.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)colon cancerbreast cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on 2023-507678-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507678-42-00.